Highlights and Quick Summary
- Net Debt/EBITDA for the quarter ending September 30, 2022 was -16.5 (a 169.12% increase compared to previous quarter)
- Year-over-year quarterly Net Debt/EBITDA increased by 943.66%
- Annual Net Debt/EBITDA for 2021 was -0.47 (a -440.48% decrease from previous year)
- Annual Net Debt/EBITDA for 2020 was 0.14 (a -83.96% decrease from previous year)
- Annual Net Debt/EBITDA for 2019 was 0.85 (a -4.3% decrease from previous year)
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Debt/EBITDA of BioCryst Pharmaceuticals, Inc.
Most recent Net Debt/EBITDAof BCRX including historical data for past 10 years.Interactive Chart of Net Debt/EBITDA of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | -16.5 | -6.13 | -3.35 | – |
| 2021 | -1.58 | -2.41 | -2.59 | -0.88 | -0.47 |
| 2020 | 0.43 | 2.26 | 3.62 | 1.49 | 0.14 |
| 2019 | 112.99 | 0.58 | 1.37 | 1.95 | 0.85 |
| 2018 | 2.95 | 3.18 | 3.69 | 3.29 | 0.89 |
| 2017 | 5.26 | 10.75 | 4.01 | 7.39 | 1.62 |
| 2016 | 3.95 | 3.31 | 3.17 | 1.89 | 0.05 |
| 2015 | 3.0 | 5.61 | -16.64 | 4.92 | 1.33 |
| 2014 | 4.91 | 11.11 | 11.54 | 0.21 | 1.62 |
| 2013 | 1.33 | 1.89 | 0.11 | -0.22 | 0.27 |
| 2012 | 0.57 | 1.46 | 0.72 | 3.01 | 0.18 |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology